According to the World Health Organization (WHO), there was an estimated 1.8 million deaths in 2020 from lung cancer. Since it is a leading cause of cancer deaths, early detection and treatment of lung cancer became more important.
Following this trend, a Korean company has developed AI-based analysis and diagnostic solutions that can detect lung nodules and lesions on chest CT scans with deep-learning approach. Such developments promise to make lung-cancer screening more precise and accessible to all.
The main function of this solution is to carry out an automated and interconnected medical diagnostic process to minimize the error in diagnostic results. It has 95% analytical sensitivity and 98% accuracy (based on clinical test).
The company has developed its own tool for collecting CT scans as a data, which is useful to gather users’ feedback and operate a systematic labeling system that can be applied in various ways.
Since the solution transmits the relevant information to a specific viewer or shows them on an analysis report, it can conveniently facilitate the overall process required for a specialist to read medical images. In addition, by taking advantage of the fact that the founder of the company is a professor at university hospital, it has a great research infrastructure and clinical research experience with know-how on managing clinical image data and can easily obtain them.
Moreover, the solution is installed as a software program in cloud computing environment which enable to provide the service with low price at the first stage. Also, the company has already set up the analysis service on medical image in the form of SaaS (Software-as-a-Service, SaaS).
The company is currently seeking global distributors including hospitals in order to secure distribution channels, especially in the field of medical or healthcare. Considering partnership types could be varied according to the type of partner as below:
1) medical software resellers/distributors, medical imaging companies, tele-radiology service companies: commercial agency agreement and distribution services agreement
2) hospitals: license agreement
Advantages & innovations
- Lung cancer screening solutions with four-dimensional AI-based diagnostic algorithm system that can detect/quantify/track lesions on chest CT by securing clinical data
- Reduction of medical costs
- 95% of analytical sensitivity and 98% of accuracy (based on clinical test)
- Suitable for cloud service by securing short analysis time and high accuracy with limited hardware resource
- Improving reading efficiency by offering web browser-based interface and reducing human error
- An interworking system linked with Interface and PACS (Picture Archiving and Communication System) optimized for clinical reading and data collection
- Providing of comparative analysis between current and previous CT images
Stage of development
Available for demonstration
Partner sought
- Type of partner sought: company, public research institute, hospital
- Specific area of activity of the partner: medical software resellers/distributors, medical imaging companies, tele-radiology service companies, hospitals
- Task to be performed: sales, maintaining solutions, system integration & management, seeking/matching end-user.
The company is seeking partnerships with medical software resellers/distributors, medical imaging companies, tele-radiology service companies as well as great hospitals who can be in charge of local sales, maintaining solutions, and seeking/matching end-user under commercial agency agreement, distribution services agreement and license agreement.